MONTREAL, QC & TORONTO, ON- Cyclenium Pharma Inc. and the Hospital for Sick Children (SickKids) have entered into a research agreement designed to discover novel modulators for multiple new and existing biological targets of pharmacological interest across a variety of disease areas, including cardiovascular, immunology and oncology.
Cylenium is a company focused on discovery and development of novel drug candidates through the use of its proprietary macrocyclic chemistry. The collaboration will give SickKids researchers immediate access to the company’s QUEST Library™ of next generation macrocyclic molecules and associated chemical hit and lead optimization capabilities. The initial objective of the partnership is to identify compounds capable of interacting with specific therapeutic targets being studied at SickKids, thereby providing tools to improve the understanding of their involvement in the pathophysiology of specific diseases, with the ultimate goal of discovering novel therapeutic or diagnostic agents.
“We are delighted that a distinguished institution like SickKids is interested in the power and capabilities of our small molecule macrocyclic technology to contribute to their cutting-edge research efforts,” said Cyclenium president, CSO and CEO Dr. Helmut Thomas.
He adds that the library will be made available to researchers through the SickKids Proteomics, Analytics, Robotics & Chemical Biology Centre (SPARC BioCentre). The SPARC BioCentre is a high-throughput drug screening facility at SickKids. One of the first studies to be initiated involves targets implicated for the treatment of cancer and immune disorders.
For Cyclenium, this is the latest in an extensive series of international discovery collaborations established with prominent companies and research institutions to explore the exciting potential of its unique macrocycle chemistry technology, including Astellas Pharma, Haplogen GmbH, Fundación MEDINA, German Cancer Research Center (DKFZ), McGill University/Goodman Cancer Research Centre, Institute for Research in Immunology and Cancer (IRIC)/Université de Montréal, and Southern Research Institute.